Actively Recruiting
4-L Split-dose Polyethylene Glycol and Bisacodyl and Docusate Sodium Regimen Versus 2-L Split-dose Polyethylene Glycol Plus Oral Simethicone Regimen for Bowel Preparation Before Colonoscopy
Led by Tanta University · Updated on 2026-01-09
450
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this randomized controlled trial is to compare the safety, compliance, and efficacy of different bowel preparation methods prior to colonoscopy. Researchers will compare 4-L split-dose polyethylene glycol and the bisacodyl + docusate sodium regimen versus 2-L split-dose polyethylene glycol plus oral simethicone regimen versus the conventional method for bowel preparation before colonoscopy. Participants will undergo history-taking, clinical examination, laboratory investigations, and colonoscopy. Patients will be randomly assigned to receive 4-L split-dose polyethylene glycol and bisacodyl + docusate sodium, a 2-L split-dose polyethylene glycol regimen plus oral simethicone, or 2-L split-dose polyethylene glycol alone as a control. Colonoscopy will be done 24 hrs after the start of medication. Researchers will assess the quality of the bowel preparation using the Aronchick bowel preparation scale. Researchers will also assess the number of adverse events and ask the patients about the ease of bowel preparation administration, tolerability of preparation regimen, and willingness to take the same agent again for a repeat colonoscopy in the future.
CONDITIONS
Official Title
4-L Split-dose Polyethylene Glycol and Bisacodyl and Docusate Sodium Regimen Versus 2-L Split-dose Polyethylene Glycol Plus Oral Simethicone Regimen for Bowel Preparation Before Colonoscopy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing colonoscopy as a day-care procedure for various reasons such as lower gastrointestinal bleeding, colorectal cancer screening, or altered bowel habits
- Patients of any sex aged over 18 years and under 70 years
- Patients willing to provide written informed consent
You will not qualify if you...
- Having kidney failure, cirrhosis, ascites, congestive cardiac failure, bleeding disorders, seizure disorder, gastrointestinal obstruction, or perforation
- History of serious side effects to other electrolyte-based bowel cleansing treatments
- Pregnant, breastfeeding, or planning pregnancy (female patients)
- Known allergy to study treatments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta University Hospitals
Tanta, Gharbyea, Egypt, 31516
Actively Recruiting
Research Team
R
Rania M Elkafoury, MD
CONTACT
N
Nabila A Elgazzar, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here